| Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling P Roswall, M Bocci, M Bartoschek, H Li, G Kristiansen, S Jansson, S Lehn, ... Nature medicine 24 (4), 463, 2018 | 83 | 2018 |
| Evolution of anti-HER2 therapies for cancer treatment S Parakh, HK Gan, AC Parslow, IJG Burvenich, AW Burgess, AM Scott Cancer treatment reviews 59, 1-21, 2017 | 66 | 2017 |
| Biodistribution and planar gamma camera imaging of 123I-and 131I-labeled F (ab′) 2 and Fab fragments of monoclonal antibody 14C5 in nude mice bearing an A549 lung tumor IJG Burvenich, S Schoonooghe, P Blanckaert, K Bacher, L Vervoort, ... Nuclear medicine and biology 34 (3), 257-265, 2007 | 36 | 2007 |
| In vitro and In vivo targeting properties of iodine-123-or iodine-131–labeled monoclonal antibody 14C5 in a non–small cell lung cancer and colon carcinoma model I Burvenich, S Schoonooghe, B Cornelissen, P Blanckaert, E Coene, ... Clinical cancer research 11 (20), 7288-7296, 2005 | 35 | 2005 |
| Monoclonal antibody 14C5 targets integrin αvβ5 I Burvenich, S Schoonooghe, L Vervoort, C Dumolyn, E Coene, ... Molecular cancer therapeutics 7 (12), 3771-3779, 2008 | 25 | 2008 |
| Synthesis, biodistribution and effects of farnesyltransferase inhibitor therapy on tumour uptake in mice of 99mTc labelled epidermal growth factor B Cornelissen, V Kersemans, I Burvenich, R Oltenfreiter, ... Nuclear medicine communications 26 (2), 147-153, 2005 | 23 | 2005 |
| Molecular imaging of death receptor 5 occupancy and saturation kinetics in vivo by humanized monoclonal antibody CS-1008 IJG Burvenich, FT Lee, GA Cartwright, GJ O'Keefe, D Makris, D Cao, ... Clinical Cancer Research 19 (21), 5984-5993, 2013 | 18 | 2013 |
| Molecular imaging of T cell co-regulator factor B7-H3 with 89Zr-DS-5573a IJG Burvenich, S Parakh, FT Lee, N Guo, Z Liu, HK Gan, A Rigopoulos, ... Theranostics 8 (15), 4199, 2018 | 17 | 2018 |
| Molecular imaging and quantitation of EphA2 expression in xenograft models with 89Zr-DS-8895a IJG Burvenich, S Parakh, HK Gan, FT Lee, N Guo, A Rigopoulos, ST Lee, ... Journal of Nuclear Medicine 57 (6), 974-980, 2016 | 15 | 2016 |
| Preclinical evaluation of monoclonal antibody 14C5 for targeting pancreatic cancer L Vervoort, I Burvenich, S Staelens, C Dumolyn, E Waegemans, ... Cancer Biotherapy and Radiopharmaceuticals 25 (2), 193-205, 2010 | 15 | 2010 |
| Effect of cyclosporin A administration on the biodistribution and multipinhole μSPECT imaging of [123 I] R91150 in rodent brain P Blanckaert, I Burvenich, S Staelens, S De Bruyne, L Moerman, L Wyffels, ... European journal of nuclear medicine and molecular imaging 36 (3), 446-453, 2009 | 13 | 2009 |
| Radiolabeling, biodistribution, and dosimetry of 123I-mAb 14C5: a new mAb for radioimmunodetection of tumor growth and metastasis in vivo CMM Lahorte, K Bacher, I Burvenich, ED Coene, C Cuvelier, C De Potter, ... Journal of Nuclear Medicine 45 (6), 1065-1073, 2004 | 13 | 2004 |
| Receptor occupancy imaging studies in oncology drug development IJG Burvenich, S Parakh, AC Parslow, ST Lee, HK Gan, AM Scott The AAPS journal 20 (2), 1-16, 2018 | 12 | 2018 |
| PH1-derived bivalent bibodies and trivalent tribodies bind differentially to shed and tumour cell-associated MUC1 S Schoonooghe, I Burvenich, L Vervoort, F De Vos, N Mertens, J Grooten Protein Engineering, Design & Selection 23 (9), 721-728, 2010 | 12 | 2010 |
| Bifunctional aptamer–doxorubicin conjugate crosses the blood–brain barrier and selectively delivers its payload to EpCAM-positive tumor cells J Macdonald, D Denoyer, J Henri, A Jamieson, IJG Burvenich, N Pouliot, ... Nucleic acid therapeutics 30 (2), 117-128, 2020 | 11 | 2020 |
| Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice TM Shekhar, IJG Burvenich, MA Harris, A Rigopoulos, D Zanker, ... BMC cancer 19 (1), 1-18, 2019 | 11 | 2019 |
| Engineering anti-Lewis-Y hu3S193 antibodies with improved therapeutic ratio for radioimmunotherapy of epithelial cancers IJG Burvenich, FT Lee, GJ O’Keefe, D Makris, D Cao, S Gong, ... EJNMMI research 6 (1), 1-13, 2016 | 11 | 2016 |
| In vitro and in vivo evaluation of 89zr-DS-8273a as a theranostic for anti-death receptor 5 therapy IJG Burvenich, FT Lee, N Guo, HK Gan, A Rigopoulos, AC Parslow, ... Theranostics 6 (12), 2225, 2016 | 9 | 2016 |
| New strategies in polypeptide and antibody synthesis: an overview N Mertens, F Devos, J Leoen, E Van Deynse, A Willems, S Schoonooghe, ... Cancer Biotherapy and Radiopharmaceuticals 19 (1), 99-109, 2004 | 9 | 2004 |
| Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis ZD Nassar, CY Mah, J Dehairs, IJG Burvenich, S Irani, MM Centenera, ... Elife 9, e54166, 2020 | 8 | 2020 |
